Liraglutide and Dpp-4 inhibitors – side effects comparative clinical study
Abstract
The objective of this study was to monitor the side effects of the GLP-1 receptor
agonist liraglutide in comparison to those of DPP-4 inhibitors (sitagliptin and
vildagliptin), in order to determine their safety, tolerability and therapeutic efficiency.
The study was carried out in the “Heart and Diabetes Center NRW“ and included
overweight patients with type 2 diabetes whose therapeutic regimen was switched to
liraglutide or DPP-4 inhibitors. A validated questionnaire method was used to monitor
the side effects during the hospitalization period, then again at 3, and 6 months after the
beginning of the therapy.
The therapy with liraglutide was associated with more side effects than the one
with DPP-4 inhibitors. In general, side effects were declining with time, thus only few
patients stopped therapy. The incretin therapy turned out to be a safe and effective
therapeutic option for patients with type 2 diabetes mellitus.
agonist liraglutide in comparison to those of DPP-4 inhibitors (sitagliptin and
vildagliptin), in order to determine their safety, tolerability and therapeutic efficiency.
The study was carried out in the “Heart and Diabetes Center NRW“ and included
overweight patients with type 2 diabetes whose therapeutic regimen was switched to
liraglutide or DPP-4 inhibitors. A validated questionnaire method was used to monitor
the side effects during the hospitalization period, then again at 3, and 6 months after the
beginning of the therapy.
The therapy with liraglutide was associated with more side effects than the one
with DPP-4 inhibitors. In general, side effects were declining with time, thus only few
patients stopped therapy. The incretin therapy turned out to be a safe and effective
therapeutic option for patients with type 2 diabetes mellitus.
Keywords
liraglutide, DPP-4 inhibitors, side effects